CC-90011
Drug
Celgene Corporation
Total Payments
$52,024
Transactions
33
Doctors
12
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $42,272 | 25 | 9 |
| 2018 | $9,752 | 8 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,660 | 12 | 78.2% |
| Unspecified | $8,891 | 1 | 17.1% |
| Food and Beverage | $1,364 | 12 | 2.6% |
| Travel and Lodging | $1,108 | 8 | 2.1% |
Payments by Type
General
$43,133
32 transactions
Research
$8,891
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Ph 1 CC-90011 in adv Solid Tumors and NHL (CC-90011-ST-001) (CC-90011-ST-001) | Celgene Corporation | $8,891 | 0 |
Top Doctors Receiving Payments for CC-90011
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $8,891 | 1 |
| , M.D., PH.D | Hematology & Oncology | New York, NY | $4,844 | 4 |
| , M.D | Hematology & Oncology | New Haven, CT | $4,136 | 4 |
| , M.D | Urology | Philadelphia, PA | $3,805 | 3 |
| , MD | Urology | Cleveland, OH | $3,746 | 3 |
| , MD | Internal Medicine | Detroit, MI | $3,728 | 3 |
| Felix Feng | — | Ann Arbor, MI | $3,726 | 3 |
| , M.D | Medical Oncology | Boston, MA | $3,710 | 2 |
| , MD | Medical Oncology | Boston, MA | $3,710 | 2 |
| , M.D | Medical Oncology | Baltimore, MD | $3,710 | 2 |
| , M.D | Medical Oncology | Los Angeles, CA | $3,110 | 2 |
| , MD | Medical Oncology | Saint Louis, MO | $2,524 | 2 |
| , MD, MPH | Hematology & Oncology | Philadelphia, PA | $2,384 | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $52,024
Product Information
- Type Drug
- Total Payments $52,024
- Total Doctors 12
- Transactions 33
About CC-90011
CC-90011 is a drug associated with $52,024 in payments to 12 healthcare providers, recorded across 33 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $42,272 was paid across 25 transactions to 9 doctors.
The most common payment nature for CC-90011 is "Consulting Fee" ($40,660, 78.2% of total).
CC-90011 is associated with 1 research study, including "Ph 1 CC-90011 in adv Solid Tumors and NHL (CC-90011-ST-001) (CC-90011-ST-001)" ($8,891).